Roche


Roche   link
Location: Basel
Bâle

Discipline: Pharmacology

Roche is the world’s number 1 in biotech with several biopharmaceuticals on the market. Over half of the compounds in the product pipeline are biopharmaceuticals, enabling Roche to deliver better-targeted therapies.

Pharmacology - Health - Nov 13
Phesgo offers faster and less invasive delivery of standard of care treatment with Perjeta and Herceptin, under the skin in just minutes, compared to hours with intravenous infusion 1,2,3 Subcutaneous administration is preferred by patients, physicians and healthcare providers, and can be associated with reduced hospital times and costs 4,5,6 Th
Pharmacology - Event - Nov 5

New data for Roche's CD20xCD3 bispecific antibodies will be featured, as well as first clinical data on cevostamab, a first-of-its-kind FcRH5xCD3 bispecific antibody, in multiple myeloma Longer-term data for Roche's approved therapies in haemophilia A, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, reinforce the favourable effi

Pharmacology - Health - Aug 17

First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology Approval su

Pharmacology - Health - Jul 13

Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3

Pharmacology - Health - Jan 27

Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Pharmacology - Health - Dec 16, 2019

All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.

Health - Pharmacology - Oct 13

The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry analysers which are widely available around the world, thus helping to increase testing capacity In combination with other COVID-19 diagnostic tests, the

Pharmacology - Health - Aug 10

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA

Pharmacology - Health - May 28

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra /RoActemra (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.

Pharmacology - Health - Jan 21

Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma Polivy approval is based on a phase Ib/II study, the first and only study showing improved response rates a

Pharmacology - Health - Dec 13, 2019

Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf.